Covalent binding of a reactive metabolite derived from propranolol and its active metabolite 4-hydroxypropranolol to hepatic microsomal proteins of the rat

Chemical Research in Toxicology

Volumn 10, Issue 3, 1997, Pages 289-295

  Narimatsu, Shizuo ^a   Arai, Takayuki ^a   Watanabe, Toshiyuki ^a   Masubuchi, Yasuhiro ^a   Horie, Toshiharu ^a   Suzuki, Tokuji ^a   Ishikawa, Tsutomu ^a   Tsutsui, Michio ^b   Kumagai, Yoshito ^c   Cho, Arthur K ^d  

^a CHIBA UNIVERSITY   (Japan)

^b Central Laboratory   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE; 4 HYDROXYPROPRANOLOL; CYTOCHROME P450; LIVER PROTEIN; OXIDOREDUCTASE; PROPRANOLOL; SUPEROXIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INHIBITION; HYPERTENSION; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BIOTRANSFORMATION; CARBON MONOXIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; FEMALE; MALE; MICROSOMES, LIVER; NAPHTHALENES; PHENOBARBITAL; PROPRANOLOL; PROTEIN BINDING; RABBITS; RATS; SUPEROXIDES;

EID: 0030938658     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx960165e     Document Type: Article

References (38)

1. Otton, S. V., Inaba, T., and Kalow, W. (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 34, 73-80.
2. Distlerath, L. M., and Guengerich, F. P. (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogues rat enzymes. Proc. Natl. Acad. Sci. U.S.A. 81, 7348-7352.
3. Otton, S. V., Gillam, E. M. J., Lennard, M. S., Tucker, G. T., and Woods, H. F. (1990) Prorpanolol oxidation by human liver microsomes - the use of cumene hydroperoxide to probe isoenzyme specificity and regio- and stereoselectivity. Br. J. Clin. Pharmacol. 30, 751-760.
4. Eichelbaum, E., and Gross, A. S. (1990) The genetic polymorphism of debrisoquine/sparteine metabolism 9 clinical aspects. Pharmacol. Ther. 46, 377-394.
5. Gonzalez, F. J., and Meyer, U. A. (1991) Molecular genetics of the debrisoquine/sparteine polymorphism. Clin. Pharmacol. Ther. 50, 233-238.
6. Lennard, M. S., Jackson, P. R., Freestone, S., Tucker, G. T., Ramsay, L. E., and Woods, H. F. (1984) The relationship between debrisoquine oxidation phenotype and pharmacokinetics and pharmacodynamics of propranolol. Br. J. Clin. Pharmacol. 17, 679-685.
7. Raghuram, T. C., Koshakji, P. K., Wilkinson, G. R., and Wood, A. J. J. (1984) Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not bata blockade. Clin. Pharmacol. Ther. 36, 51-56.
8. Ward, S. A., Walle, T., Walle, U. K., Wilkinson, G. R., and Branch, R. A. (1989) Propranolol's metabolism is determined by both mephenytoin and debrisoquine hydroxylase activities. Clin. Pharmacol. Ther. 45, 72-79.
9. Evans, G. H., and Shand, D. G. (1973) Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin. Pharmacol. Ther. 4, 487-493.
10. Straka, R. J., Lalonde, R. L., Pieper, J. A., Bottorff, M. B., and Mirvis, D. M. (1987) Nonlinear pharmacokinetics of unbound propranolol after oral administration. J. Pharm. Sci. 76, 521-524.
11. Schneck, D. W., and Prichard, J. F. (1981) The inhibitory effect of propranolol pretreatment on its own metabolism in the rats. J. Pharmacol. Exp. Ther. 218, 575-581.
12. Shaw, L., Lennard, M. S., Tucker, G. T., Bax, N. D. S., and Woods, H. F. (1987) Irreversible binding and metabolism of propranolol by human liver microsomes - Relationship to polymorphic oxidation. Biochem. Pharmacol. 36, 2283-2288.
13. Masubuchi, Y., Fujita, S., Chiba, M., Kagimoto, N., Umeda, S., and Suzuki, T. (1991) Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochem. Pharmacol. 41, 861-865.
14. Masubuchi, Y., Narimatsu, S., and Suzuki, T. (1992) Activation of propranolol and irreversible binding to rat liver microsomes: strain differences and effects of inhibitors. Biochem. Pharmacol. 43, 635-637.
15. Masubuchi, Y., Suzuki, K., Fujita, S., and Suzuki, T. (1992) A possible mechanism of the impairment of hepatic microsomal monooxygenase activities after multiple administration of propranolol in rats. Biochem. Pharmacol. 43, 757-762.
16. Masubuchi, Y., Narimatsu, S., Hosokawa, S., and Suzuki, T. (1994) Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. Biochem. Pharmacol. 48, 1891-1898.
17. Walle, T., Oatis, J. E., Walle, U. K., and Knapp, D. R. (1982) New ring-hydroxylated metabolites of propranolol. Species differences and stereospecific 7-hydroxylation. Drug Metab. Dispos. 10, 122-127.
18. Bargar, E. M., Walle, U. K., Bai, S. A., and Walle, T. (1983) Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography and gas chromatography - mass spectrometry techniques. Drug Metab. Dispos. 11, 266-272.
19. Fitzgerald, D. J., and O'Donnell, S. R. (1971) Pharmacology of 4-hydroxypropranolol. Br. J. Pharmacol. 43, 222-235.
20. Narimatsu, S., Watanabe, T., Masubuchi, Y., Horie, T., Kumagai, Y., Cho, A. K., Imaoka, S., Funae, Y., Ishikawa, T., and Suzuki, T. (1995) Characterization of a chemically reactive propranolol metabolite that binds to microsomal proteins of rat liver. Chem. Res. Toxicol. 8, 721-728.
21. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378.
22. Crowther, A. F., and Smith, L. H. (1967) U.S. Patent 3337628.
23. Masubuchi, Y., Hososkawa, S., Horie, T., Suzuki, T., Ohmori, S., Kitada, M., and Narimatsu, S. (1994) Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos. 22, 909-915.
24. Yasukochi, Y., and Masters, B. S. S. (1976) Some properties of detergent-solubilized NADPH-cytochrome c (cytochrome P-450) reductase purified by biospecific affinity chromatography. J. Biol. Chem. 251, 5337-5344.
25. Fujita, S., Morimoto, R., Chiba, M., Kitani, K., and Suzuki, T. (1989) Evaluation of the involvement of a male specific cytochrome P-450 isozyme in senescence-associated decline of hepatic drug metabolism in male rats. Biochem. Pharmacol. 38, 3925-3931.
26. Suzuki, T., Narimatsu, S., Fujita, S., Masubuchi, Y., Umeda, S., Imaoka, S., and Funae, Y. (1992) Purification and characterization of a cytochrome P-450 isozyme catalyzing bunitrolol 4-hydroxylation in liver microsomes of male rats. Drug Metab. Dispos. 20, 367-373.
27. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
28. Strobel, H. W., and Coon, M. J. (1971) Effects of superoxide genaration and dismutation on hydroxylation reactions catalyzed by liver microsomal cytochrome P-450. J. Biol. Chem. 246, 7827-7829.
29. Lai, C. S. T. A., Grover, T. A., and Piette, L. H. (1979) Hydroxyl radical production in a purified NADPH-cytochrome c (P-450) reductase system. Arch. Biochem. Biophys. 193, 373-378.
30. Winston, G. W., and Cederbaum, A. I. (1983) NADPH-dependent production of oxy radicals by purified components of the rat liver mixed function oxidase system. J. Biol. Chem. 258, 1508-1513.
31. Rasgba-Step, J., and Cederbaum, A. I. (1993) Generation of reactive oxygen intermediates by human liver microsomes in the present of NADPH and NADH. MoI. Pharmacol. 45, 150-157.
32. Imaoka, S., Terano, Y., and Funae, Y. (1989) Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats. J. Biochem. 105, 939-945.
33. Coon, M. J., Ding, X., Pernecky, S. J., and Vaz, A. D. N. (1992) Cytochrome P450: progress and prediction. FASEB J. 6, 669-673.
34. Seidegard, J., Depierre, J. W., Morgenstern, R., Pilotti, A., and Ernster, L. (1981) Induction of drug-metabolizing systems and related enzymes with metabolites and structural analogues of stilbene. Biochim. Biophys. Acta 672, 65-78.
35. Sawyer, D. T., and Valentine, J. S. (1981) How super is super-oxide? Acc. Chem. Res. 14, 393-400.
36. Suzuki, T., Fujita, S., Narimatsu, S., Masubuchi, Y., and Umeda, S. (1991) Impairment of bunitrolol 4-hydroxylase activity in liver microsomes of Dark Agouti rats. Biochem. Pharmacol. 42, 2241-2244.
37. Masubuchi, Y., Umeda, S., Chiba, M., Fujita, S., and Suzuki, T. (1991) Selective 3-hydroxylation deficiency of lidocaine and its metabolite in Dark Agouti rats. Biochem. Pharmacol. 42, 693-695.
38. Masubuchi, Y., Kagimoto, N., Narimatsu, S., Fujita, S., and Suzuki, T. (1993) Regioselective contribution of the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab. Dispos. 21, 1012-1016.